-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The company is focusing its efforts precisely to secure the year-end target.
Category:
发布时间：2019-12-03
【概要描述】
The fourth quarter is the golden season for the company’s production and operations, as well as the final stretch for achieving the year’s overall development objectives. In response to the call to “fight hard in the fourth quarter and fully accomplish the annual goals,” the entire organization has launched a vigorous and sustained campaign to deliver outstanding performance in the fourth quarter, ensuring the successful completion of the year’s production and operational targets.
The fourth quarter is the golden season for the company’s production and operations, as well as the final stretch for achieving the year’s overall development objectives. In response to the call to “fight hard in the fourth quarter and fully accomplish the annual goals,” the entire organization has launched a vigorous and sustained campaign to deliver outstanding performance in the fourth quarter, ensuring the successful completion of the year’s production and business targets.
Since the beginning of this year, sales of the company’s ampoule products have remained robust; as of the end of September, sales of polypropylene ampoules for water-for-injection had increased by 413% year on year. To boost production, the ampoule manufacturing workshop has proactively responded to market demand by operating at full capacity across all production lines. Production of the 5 mL and 10 mL sizes has been steadily expanded, with daily output now exceeding 220,000 units.
The sustained growth trajectory is inseparable from robust investment in R&D and innovation. Leveraging high-level innovation platforms such as the National Enterprise Technology Center, the company continuously strengthens fundamental and cutting-edge basic research, directs its innovative focus toward major national initiatives in the development of innovative drugs, and seizes opportunities to develop new and blockbuster products with significant market potential and high technological content.
In the first half of this year, the company obtained a total of 14 marketing approvals for generic drugs. Among them, tirofiban hydrochloride sodium chloride injection, a cardiovascular medication indicated for the clinical treatment of acute coronary syndromes, is a therapeutic agent with significant potential for widespread clinical adoption and represents the company’s flagship new product launched within the year.
As we enter the fourth quarter, R&D personnel are intensifying the development of innovative drugs while rallying their efforts to concentrate human and material resources on accelerating studies for the evaluation of quality and therapeutic equivalence of generic drugs, with the number of injectable dosage form applications ranking among the highest in the industry.
In response to the evolving market landscape, the operating company has aligned its strategies with prevailing trends, promptly adjusted its business direction, and intensified sales and performance evaluation for therapeutic products such as moxifloxacin hydrochloride sodium chloride injection, arbidol hydrochloride capsules, and bromhexine hydrochloride glucose injection, as well as for large-format flexible-bag formulations. While maintaining its leading position in the major intravenous infusion market, the company is also expanding its market share in the therapeutic segment.
At this critical juncture as the company races to close out the fourth quarter, the company’s trade union has issued the “Activity Plan for Launching a Sales Competition among Business Units” to further boost the work enthusiasm of sales personnel and support the achievement of the company’s annual targets, thereby rallying momentum for the fourth-quarter sales competition. Su Xuejun, the company’s general manager, stated that the company will enter the fourth quarter in peak condition, strive with full vigor to achieve outstanding results, ensure the successful completion of all annual objectives and tasks, and make new contributions to the enterprise’s high-quality development and the growth of Shijiazhuang’s pharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091